Oppenheimer downgraded Ascendis Pharma to Perform from Outperform without a price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ASND:
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Ascendis Pharma removed from Best Ideas List at Wedbush
- Ascendis Pharma downgraded to Equal Weight from Overweight at Morgan Stanley
- Ascendis Pharma price target lowered to $92 from $132 at BofA
- Ascendis Pharma Craters after Disappointing Drug News